IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Product Class Date Terms of Agreement
Niaspan (niacin)/Advicor
(niacin/lovastatin)
Leuplin /Lupron Depot
(leuprorelin)
C 2003 Takeda signed an agreement with Kos to co-promote
both products in the USA from January 2004. The deal
between TPNA and Kos will last three years, but can be
extended. If the companies do not renew the
partnership, Takeda will be eligible to receive declining
tail payments for a period of three years following 2006.
Under the agreement, Takeda’s US salesforce will
co-promote the products and Takeda will receive an
undisclosed percentage of net sales for the Kos’s current
cholesterol franchise above a specific baseline level.
L 2003 TAP obtained an exclusive license from Norwood Abbey
to expand the indications for Lupron, by using intellectual
property owned by Norwood. The two companies will
jointly fund R&D to assess several applications in fields,
with TAP taking responsibility for filing any resulting
sNDAs. TAP would be eligible to pay milestones and
royalties to Norwood, and has acquired a $2 million
equity stake in Norwood Immunology, a wholly-owned
Norwood subsidiary.
NovoNorm (repaglinide) A 2003 Licensed in from Novo Nordisk for co-marketing in Japan.
Gasmotin (mosapride) A 2003 Licensed from Dainippon Sumitomo for worldwide
development and marketing, excluding Japan, China,
Taiwan and South Korea.
Prepenon Takeda
(injectable liquid
morphine hydrochloride)
Actos (pioglitazone) A 1998/
2000
N 2000 Partnership with Terumo. Terumo will develop and
produce the product. Takeda began selling it in 2001.
In the US, Actos is co-promoted by Lilly. In Japan,
Takeda co-markets pioglitazone with Novo Nordisk.
Abbott has exclusive rights in nine Latin American
countries. In October 2004, TPNA filed through Takeda
Global Research & Development Center an NDA for
Actoplus Met (combination drug of pioglitazone and
metformin) with the FDA as a treatment for type 2
diabetes.
Flomax (tamsulosin) G 1997 Yamanouchi (now Astellas) granted Takeda co-promotion
rights in Japan to tamsulosin, an oral alpha1 antagonist,
which has been launched worldwide for the treatment of
benign prostatic hypertrophy (BPH) and urinary tract
disorders. In June 2007, Astellas submitted tamsulosin
for approval in Japan for lower urinary tract syndrome in
male patients.
© 2009 IMS Health In cor po rated or its af fil i ates Page 92